We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
This is the first international study on the incidence of Mediterranean nutrition on the side effects of cancer treatments and survival of pediatric cancer patients.
The Pediatric Oncology and Hematology Service of Vall d'Hebron University Hospital and the research group in Childhood Cancer and Blood Disorders of Vall d'Hebron Research Institute (VHIR) will participate in a 5-year prospective nutritional research project on childhood cancer and its relationship with nutrition in Southern Europe. The study, led by Columbia University Irving Medical Center (CUIMC) and the International Agency for Research on Cancer (IARC), is 100% funded by the Aladina Foundation, the leading foundation in Spain supporting children and adolescents with cancer and their families.
EpicKids, The Role of the Mediterranean Diet in the Evolution of Pediatric Cancer
EpicKids aims to develop informative guidelines based on objective data and critical nutrition parameters to help medical teams describe the trajectory of nutritional status among Southern European children and adolescents with acute lymphoblastic leukemia (ALL) and certain types of brain tumors.
During the 5-year study period, investigators will examine biological factors (microbiome/metabolome), lifestyle behaviors, sociodemographic factors and quality of life and correlate these indicators with clinical outcomes.
Data will be collected in three southern European countries (Spain, Greece and Italy) where trained staff will facilitate research objectives that adhere to standard operating procedures established by Columbia University Irving Medical Center (CUIMC), the International Initiative for Pediatrics and Nutrition (IIPAN), the International Agency for Research on Cancer (IARC), and local scientific committees composed of pediatric oncology experts from participating hospitals.
The biobank, located in Lyon (France), will be provided by IARC. The corresponding clinical data will be managed in the IIPAN REDCap database and will be managed by the IIPAN research team in New York. Through a formalized process, investigators and collaborators will have access to the data with the goal of facilitating etiological and prognostic studies related to nutrition and childhood cancer.
The combination of clinical and biological data provided by the different participating organizations will open a new field for the creation of pilot data needed for future intervention studies.
EPIC Study, European Prospective Study on Diet, Cancer and Health
EPICKids is an unprecedented international choral work in the field of pediatric oncology. This study follows the Epic Report, in which 12 European countries participated and more than half a million people were studied by analyzing dietary patterns, different biochemical parameters and survival. The results of the comparison of dietary consumption among the 23 European centers were published in 2002 and showed a protective effect of fiber, fruit and vegetable consumption on colorectal cancer, a protective effect of fruit consumption on lung cancer, and of fruit and vegetables on the upper digestive tract, while it has been confirmed that high consumption of fruit and vegetables has no effect on prostate cancer.
In addition to Vall d'Hebron, the Columbia University Irving Medical Center and the International Agency for Research against Cancer (IARC) belonging to the World Health Organization (WHO) are participating in the study as research organizations, as well as the hospitals Niño Jesús and La Paz in Madrid, Sant Joan de Déu in Barcelona, Virgen del Rocío in Seville, the Italian Fondazione Monza e Brianza and Fondazione IRCCS and the Aghia Sofia Hospital in Athens.
Investigators will examine biological factors, lifestyle behaviors, sociodemographic factors and quality of life and correlate these indicators with clinical outcomes.
Paediatric Oncology and Haematology, Children's Hospital and Woman's Hospital
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.